US 12,447,228 B2
Polymer particles
Gregory M. Cruise, Rancho Santa Margarita, CA (US); Xinping Wu, Aliso Viejo, CA (US); Gloria Hincapie, Aliso Viejo, CA (US); and Yue Wu, Aliso Viejo, CA (US)
Assigned to Terumo Corporation, Tokyo (JP)
Filed by TERUMO CORPORATION, Tokyo (JP)
Filed on Feb. 21, 2023, as Appl. No. 18/112,192.
Application 18/112,192 is a division of application No. 16/913,864, filed on Jun. 26, 2020, granted, now 11,617,814.
Application 16/913,864 is a division of application No. 16/403,364, filed on May 3, 2019, granted, now 10,729,805, issued on Aug. 4, 2020.
Application 16/403,364 is a division of application No. 15/719,197, filed on Sep. 28, 2017, granted, now 10,328,175, issued on Jun. 25, 2019.
Claims priority of provisional application 62/428,990, filed on Dec. 1, 2016.
Claims priority of provisional application 62/401,091, filed on Sep. 28, 2016.
Prior Publication US 2023/0190991 A1, Jun. 22, 2023
Int. Cl. A61L 24/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/555 (2006.01); A61K 47/69 (2017.01); A61L 24/06 (2006.01); A61L 26/00 (2006.01); A61L 31/04 (2006.01); A61L 31/14 (2006.01); C08F 220/56 (2006.01); C08F 236/20 (2006.01); A61B 17/00 (2006.01); A61B 17/12 (2006.01)
CPC A61L 24/0015 (2013.01) [A61K 31/4745 (2013.01); A61K 31/555 (2013.01); A61K 47/6927 (2017.08); A61L 24/0042 (2013.01); A61L 24/06 (2013.01); A61L 26/0014 (2013.01); A61L 26/0061 (2013.01); A61L 26/009 (2013.01); A61L 31/048 (2013.01); A61L 31/148 (2013.01); C08F 220/56 (2013.01); C08F 236/20 (2013.01); A61B 2017/00004 (2013.01); A61B 17/12109 (2013.01); A61B 17/12113 (2013.01); A61B 17/12181 (2013.01); A61L 2300/204 (2013.01); A61L 2300/224 (2013.01); A61L 2400/06 (2013.01); A61L 2430/36 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treatment comprising:
administering a solution including a plurality of particles to a treatment site;
wherein the plurality of particles include a reaction product of at least one monomer, at least one crosslinker, and at least one polymerizable pharmaceutical agent;
wherein the at least one polymerizable pharmaceutical agent is chemically bonded to the particle with a hydrolytically degradable linkage; and
wherein the at least one polymerizable pharmaceutical agent has a structure which is a polymerizable derivative of 7-ethyl-10-hydroxy-camptothecin.